| Business Summary | | Progenics
Pharmaceuticals,
Inc.
is
a
biopharmaceutical
company
focusing
on
the
development
and
commercialization
of
products
for
the
treatment
and
prevention
of
viral,
cancer
and
other
life-threatening
diseases.
The
Company
applies
its
immunology
expertise
to
develop
biopharmaceuticals
to
fight
viral
diseases,
such
as
HIV
(human
immunodeficiency
virus)
infection,
and
cancers,
such
as
malignant
melanoma
and
prostate
cancer.
Based
on
its
participation
in
the
discoveries
of
two
major
receptors
for
HIV,
the
Company
is
engaged
in
the
research
and
development
of
therapeutic
products
designed
to
block
entry
of
HIV
into
human
immune
system
cells.
The
Company
is
also
engaged
in
programs
to
discover
and
develop
novel
small-molecule
HIV
therapeutics
that
target
the
fusion
co-receptors
of
the
virus
and
other
programs
focusing
on
HIV
attachment
and
fusion. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Progenics
Pharmaceuticals
is
a
biopharmaceutical
company
focusing
on
the
development
and
commercialization
of
innovative
products
for
the
treatment
and
prevention
of
cancer,
viral
and
other
life-threatening
diseases.
For
the
six
months
ended
6/30/01,
total
revenues
rose
8%
to
$7.3
million.
Net
income
totaled
$5.7
million
vs.
a
loss
of
$2.9
million.
Results
reflect
revenues
from
the
collaborations
with
Bristol-Myers
and
Hoffman-La
Roche
and
a
$9.9
million
termination
payment. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Paul Maddon, M.D., Ph.D., 41 Chairman,
CEO, Chief Science Officer | $552K | $132K | Ronald Prentki, 43 Pres | 351K | 1.3M | Robert McKinney, 44 VP
of Fin. and Operations and Treasurer | 184K | 2.0M | Richard Krawiec, Ph.D., 53 VP
of Investor Relations and Corp. Communications | -- | -- | Robert Israel, M.D., 44 VP
of Medical Affairs | 291K | 1.9M | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|